CD44 and lung cancer: In conclusion, these findings comply with the results in the literature for (i) the importance of HA–CD44/RHAMM axis targeting in lung cancer treatment, (ii) the efficacy of TP in these attempts, and (iii) the need for the design of more sophisticated multifunctional targeted drug delivery systems with combined ECM and cancer cell targeting.